Monitor next quarterly filing for contribution of Bridgewell revenue/EBITDA and impact on Vireo's consolidated leverage. The convertible notes cannot convert until the 2nd anniversary (June 2028), so near-term dilution is limited. Watch for regulatory approvals on Nevada and Maryland dispensary deals. The conflict of interest (CEO Mazarakis is a partner at lender Chicago Atlantic) may draw shareholder scrutiny.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 12 $12.46entry
- T+1 · 5mo ago −3.69%α −5.46% · $12.00
- T+5 · 5mo ago −10.91%α −11.53% · $11.10
- T+20 · 4mo ago −19.58%α −20.84% · $10.02
- T+60 · 2mo ago −3.69%α −7.22% · $12.00
Price Chart
How similar events traded
Executive Summary
Vireo Growth Inc. closed the acquisition of Bridgewell Agribusiness LLC on June 5, 2026 for approximately $13.66 million in unsecured subordinated convertible notes, plus the assumption of ~$30.35 million in existing indebtedness. Consideration includes convertible notes with 3.85% interest, 5-year maturity, convertible at $0.62/share into an estimated 22 million subordinate voting shares. Separately, Vireo announced two small pending dispensary acquisitions in Nevada and Maryland. The deal significantly increases Vireo's leverage but adds organic food supply chain capabilities, while the CEO's affiliation with the largest debt holder (Chicago Atlantic) raises governance considerations.
Key Financial Metrics
Key Facts
- Base purchase price of $40M adjusted to ~$13.66M closing purchase price, paid via convertible notes
- Assumed ~$30.35M in total debt, including $22M senior secured loan from Chicago Atlantic (affiliate of CEO John Mazarakis)
- Convertible notes aggregate ~$13.66M at 3.85% interest, maturing in 5 years, convertible at $0.62/share for ~22M shares
- Bridgewell is an organic/non-GMO food ingredient supply chain business, not cannabis
- Two pending dispensary acquisitions: Nevada ($500k total, $290k cash + stock) and Maryland ($1.55M total, $400k cash + note + stock)
- Post-transaction, ultimate sellers hold ~1.0% of Vireo on a fully diluted basis
- Sellers include non-compete covenants for 3-5 years in broad restricted area
- Market consensus is 0% bullish (3 hold, 4 sell, 2 strong sell)
Financial Impact
Total purchase consideration of ~$13.66M in convertible notes plus assumption of ~$30.35M in debt (total ~$44M). Convertible note interest rate 3.85%. Conversion at $0.62/share would add ~22M shares (pre-consolidation). CEO's affiliate holds $22M senior secured loan.
Risk Factors
- Significant debt load (~$30M assumed + $13.66M convertible notes) with no disclosed revenue from acquired business
- Insider conflict: CEO John Mazarakis is a partner at Chicago Atlantic Group, which holds the $22M senior secured loan
- Convertible notes create future dilution; full conversion adds ~22M shares (~1% fully diluted currently but could increase with adjustments)
- Dispensary acquisitions subject to regulatory approvals, not guaranteed to close
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-072936 |
| Document: tm2617497d2_ex4-1.htm | 0001104659-26-072936 |
| Document: tm2617497d2_8k.htm | 0001104659-26-072936 |
| Document: tm2617497d2_ex99-1.htm | 0001104659-26-072936 |
| Document: 0001104659-26-072936-index-headers.html | 0001104659-26-072936 |
| Document: 0001104659-26-072936-index.html | 0001104659-26-072936 |
| Document: 0001104659-26-072936.txt | 0001104659-26-072936 |
Track record
21 reports on VREOF
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +18.71% at T+60 after the Jun 18, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago 3 Neutral 3/10 Entry $6.13 Now $6.29 +2.68% settles Feb 11
- Nov 13, 20263d ago 3 Neutral 2/10 Entry $6.13 Now $6.29 +2.68% settles Feb 11
- Nov 10, 20266d ago SC 13D/A Neutral 4/10 Entry $6.74 Now $6.29 −6.68% settles Feb 9
- Nov 10, 20266d ago 8-K Neutral 5/10 Entry $6.68 Now $6.29 −5.84% settles Feb 8
- Nov 3, 202614d ago EFFECT Neutral 4/10 Entry $7.45 Now $6.29 −15.57% settles Feb 1
- Oct 30, 202617d ago S-4/A Neutral 5/10 Entry $7.36 Now $6.29 −14.54% settles Jan 29
- Oct 9, 20265w ago S-4 Neutral 5/10 Entry $9.15 Now $6.29 −31.23% settles Jan 7
- Oct 8, 20265w ago 8-K Bullish 6/10 Entry $9.38 Now $6.29 −32.94% settles Jan 6
- Aug 18, 202612w ago 8-K Neutral 3/10 Entry $10.97 to $6.79 Now $6.29 −42.66% ▼ −38.10% −37.28% vs SPY
- Aug 11, 202613w ago 8-K Mixed 6/10 Entry $10.64 to $7.36 Now $6.29 −40.88% ▼ −30.83% −30.69% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers